Rosuvastatin

Rosuvastatin, also known as S-4522 and ZD 4522, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar to that of other statins. Its approximate elimination half life is 19 h and its time to peak plasma concentration is reached in 3–5 h following oral administration. Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.

Properties:
Density: 1.368 g/cm3
Boiling Point: 745.6ºC at 760 mmHg
Flash Point: 404.7ºC
Refractive Index: 1.597
Vapor Pressure: 2.38E-23mmHg at 25°C

HMG-CoA Reductase Inhibitors Related Prodcuts:

Simvastatin; Rosuvastatin calcium; Lovastatin; Pitavastatin Calcium; Simvastatin ammonium salt; Rosuvastatin Sodium; Rosuvastatin ethyl ester; Pitavastatin; Pravastatin Sodium

[1]. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44.

[2]. Schneck, D.W., et al., The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther, 2004. 75(5): p. 455-63.

[3]. Kim, Y.S., et al., Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol, 2007. 49(6): p. 376-83.